Literature DB >> 16800784

The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation.

Annika Antonsson1, Elizabeth Payne, Kylie Hengst, Nigel A J McMillan.   

Abstract

It is critical that viruses are able to avoid the antiviral activities of interferon (IFN). We have shown previously that the human papillomavirus (HPV) is able to avoid IFN-alpha via interaction of the HPV-16 E7 protein with IFN regulatory factor-9 (IRF-9). Here, we investigated the details of the interaction using HPV-16 E7 peptide mapping to show that IRF-9 binds HPV-16 E7 in a domain encompassing amino acids 25-36. A closer examination of this region indicates this is a novel proline, glutamate, serine, and threonine-rich (PEST) domain, with a PEST score of 8.74. We have also mapped the region of interaction within IRF-9 and found that amino acids 354-393 play an important role in binding to HPV-16 E7. This region of IRF-9 encompasses the IRF association domain (IAD), a region important for protein-protein interaction central to IRF function. Finally, we used alanine-scanning mutagenesis to determine if E7-IRF-9 interaction was important for E7-mediated cellular transformation and found that the HPV-16 E7 mutants Y25A, E26A, S31A, S32A, and E35A, but not L28A and N29A, caused loss of transformation ability. Preliminary data suggest loss of IRF-9 interaction with E7 mutants correlated with transformation. Our work suggests E7-IRF-9 interaction is important for the transforming ability of HPV-16 E7 and that HPV-16 E7 may interact with other IRF proteins that have IAD domains.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16800784     DOI: 10.1089/jir.2006.26.455

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  22 in total

Review 1.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

Review 2.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

Review 3.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

4.  High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression.

Authors:  Jeanette Reiser; José Hurst; Maike Voges; Peter Krauss; Peter Münch; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

Review 5.  Antiviral immune responses in the genital tract: clues for vaccines.

Authors:  Akiko Iwasaki
Journal:  Nat Rev Immunol       Date:  2010-09-10       Impact factor: 53.106

6.  Blood pressure homeostasis is maintained by a P311-TGF-β axis.

Authors:  Kameswara Rao Badri; Ming Yue; Oscar A Carretero; Sree Latha Aramgam; Jun Cao; Stephen Sharkady; Gene H Kim; Gregory A Taylor; Kenneth L Byron; Lucia Schuger
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 7.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Expression of human papilloma virus type 16 antigens, specific targeting as well as formation of virus-like particles by HSV-1 amplicon vectors.

Authors:  Sabine Schenck; Elke Kehm; Alberto L Epstein; Hanswalter Zentgraf; Martin Müller; Charles W Knopf
Journal:  Virus Genes       Date:  2008-06-12       Impact factor: 2.332

Review 9.  The papillomavirus E7 proteins.

Authors:  Ann Roman; Karl Munger
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

10.  Biomarkers in cervical cancer.

Authors:  Eun-Kyoung Yim; Jong-Sup Park
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.